The Food and Drug Administation is approving a generic drug for a very rare genetic disorder, but not for autism.

COPENHAGEN, March 10 (Reuters) - Novo Nordisk said on Tuesday it had received a warning letter from the U.S. Food and Drug ...

The FDA announced a new approved use for the drug leucovorin, which Trump has touted as a treatment for autism. But the ...

The U.S. Food and Drug Administration (FDA) has issued a warning to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications, ...

The Trump administration explored giving the green light to a potential treatment for a broad swath of people on the autism spectrum — but a new drug approval scales back those ...

The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism symptoms.

The Food and Drug Administration is expanding approval of leucovorin to treat an ultra-rare genetic condition.

The prescription drug leucovorin is getting a label update, though it’s not what that the US Food and Drug Administration suggested might be coming during a White House briefing in September, when ...

The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.

The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster medications.

In a post on social media Friday, FDA Commissioner Marty Makary announced that Prasad will exit in April, adding that he got “a tremendous amount accomplished” during his year at the agency. Prasad’s ...

In September, the Trump administration took what it called “bold actions” on autism that included touting the generic drug leucovorin as a promising treatment. In a news release, Marty Makary, ...